383 related articles for article (PubMed ID: 28884937)
61. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability.
Luther J; Higgins PD; Schoenfeld PS; Moayyedi P; Vakil N; Chey WD
Am J Gastroenterol; 2010 Jan; 105(1):65-73. PubMed ID: 19755966
[TBL] [Abstract][Full Text] [Related]
62. Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains.
Molina-Infante J; Pazos-Pacheco C; Vinagre-Rodriguez G; Perez-Gallardo B; Dueñas-Sadornil C; Hernandez-Alonso M; Gonzalez-Garcia G; Mateos-Rodriguez JM; Fernandez-Bermejo M; Gisbert JP
Helicobacter; 2012 Aug; 17(4):269-76. PubMed ID: 22759326
[TBL] [Abstract][Full Text] [Related]
63. Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori.
Sue S; Shibata W; Sasaki T; Kaneko H; Irie K; Kondo M; Maeda S
J Gastroenterol Hepatol; 2019 Apr; 34(4):686-692. PubMed ID: 30151994
[TBL] [Abstract][Full Text] [Related]
64. PPI-amoxicillin dual therapy four times daily is superior to guidelines recommended regimens in the Helicobacter pylori eradication therapy within Asia: A systematic review and meta-analysis.
Li C; Shi Y; Suo B; Tian X; Zhou L; Song Z
Helicobacter; 2021 Aug; 26(4):e12816. PubMed ID: 34002433
[TBL] [Abstract][Full Text] [Related]
65. Research trends on vonoprazan-based therapy for Helicobacter pylori eradication: A bibliometric analysis from 2015 to 2023.
Du RC; Ouyang YB; Lu NH; Hu Y
Helicobacter; 2023 Oct; 28(5):e13012. PubMed ID: 37515414
[TBL] [Abstract][Full Text] [Related]
66. Pharmacological regimens for eradication of Helicobacter pylori: an overview of systematic reviews and network meta-analysis.
Xin Y; Manson J; Govan L; Harbour R; Bennison J; Watson E; Wu O
BMC Gastroenterol; 2016 Jul; 16(1):80. PubMed ID: 27460211
[TBL] [Abstract][Full Text] [Related]
67. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a systematic review of recent evidence.
Kate V; Kalayarasan R; Ananthakrishnan N
Drugs; 2013 Jun; 73(8):815-24. PubMed ID: 23625272
[TBL] [Abstract][Full Text] [Related]
68. The efficacy of vonoprazan combined with different dose amoxicillin on eradication of
Lin Y; Xu H; Yun J; Yu X; Shi Y; Zhang D
Ann Transl Med; 2022 Sep; 10(18):987. PubMed ID: 36267745
[TBL] [Abstract][Full Text] [Related]
69. Helicobacter pylori eradication with moxifloxacin-containing therapy following failed first-line therapies in South Korea.
Kang KK; Lee DH; Oh DH; Yoon H; Shin CM; Park YS; Kim N; Jung HC
World J Gastroenterol; 2014 Jun; 20(22):6932-8. PubMed ID: 24944485
[TBL] [Abstract][Full Text] [Related]
70. Vonoprazan-Based Third-Line Therapy Has a Higher Eradication Rate against Sitafloxacin-Resistant Helicobacter pylori.
Saito Y; Konno K; Sato M; Nakano M; Kato Y; Saito H; Serizawa H
Cancers (Basel); 2019 Jan; 11(1):. PubMed ID: 30669474
[TBL] [Abstract][Full Text] [Related]
71. Helicobacter pylori eradication therapy outcome according to clarithromycin susceptibility testing in Japan.
Horie R; Handa O; Ando T; Ose T; Murakami T; Suzuki N; Sendo R; Imamoto E; Itoh Y
Helicobacter; 2020 Aug; 25(4):e12698. PubMed ID: 32368846
[TBL] [Abstract][Full Text] [Related]
72. Efficacy of bismuth for antibiotic-resistant Helicobacter pylori strains eradication: A systematic review and meta-analysis.
Han Z; Li Y; Kong Q; Liu J; Wang J; Wan M; Lin M; Lin B; Zhang W; Ding Y; Wang S; Mu Y; Duan M; Zuo X; Li YQ
Helicobacter; 2022 Dec; 27(6):e12930. PubMed ID: 36156332
[TBL] [Abstract][Full Text] [Related]
73. Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related Diseases.
Yang X; Li Y; Sun Y; Zhang M; Guo C; Mirza IA; Li YQ
Dig Dis Sci; 2018 Feb; 63(2):302-311. PubMed ID: 29282636
[TBL] [Abstract][Full Text] [Related]
74. The efficacy and safety of vonoprazan-amoxicillin dual therapy in eradicating Helicobacter pylori: a systematic review and meta-analysis.
Feng JH; Cheng J; Lao YJ; Huang K; Mou JL; Hu F; Lin ML; Lin J
Eur J Med Res; 2023 Aug; 28(1):272. PubMed ID: 37550781
[TBL] [Abstract][Full Text] [Related]
75. Efficacy and safety of low-dose rifabutin-based 7-day triple therapy as a third- or later-line Helicobacter pylori eradication regimen.
Inokuchi K; Mori H; Matsuzaki J; Hirata K; Harada Y; Saito Y; Suzuki H; Kanai T; Masaoka T
Helicobacter; 2022 Aug; 27(4):e12900. PubMed ID: 35644041
[TBL] [Abstract][Full Text] [Related]
76. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis.
Zhao F; Wang J; Yang Y; Wang X; Shi R; Xu Z; Huang Z; Zhang G
Helicobacter; 2008 Dec; 13(6):532-41. PubMed ID: 19166419
[TBL] [Abstract][Full Text] [Related]
77. Efficacy of second-line regimens for
Chang YL; Tung YC; Tu YK; Yeh HZ; Yang JC; Hsu PI; Kim SE; Wu MF; Liou WS; Shiu SI
BMJ Open Gastroenterol; 2020 Sep; 7(1):. PubMed ID: 32883715
[TBL] [Abstract][Full Text] [Related]
78. Safety of first-line triple therapy with a potassium-competitive acid blocker for Helicobacter pylori eradication in children.
Kusano C; Gotoda T; Suzuki S; Ikehara H; Moriyama M
J Gastroenterol; 2018 Jun; 53(6):718-724. PubMed ID: 29110085
[TBL] [Abstract][Full Text] [Related]
79. Triple therapy with high-dose proton-pump inhibitor, amoxicillin, and doxycycline is useless for Helicobacter pylori eradication: a proof-of-concept study.
Almeida N; Romãozinho JM; Donato MM; Luxo C; Cardoso O; Cipriano MA; Marinho C; Sofia C
Helicobacter; 2014 Apr; 19(2):90-7. PubMed ID: 24506175
[TBL] [Abstract][Full Text] [Related]
80. Novel and Effective Therapeutic Regimens for
Hu Y; Zhu Y; Lu NH
Front Cell Infect Microbiol; 2017; 7():168. PubMed ID: 28529929
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
